scispace - formally typeset
C

Christof M. Kramm

Researcher at University of Göttingen

Publications -  180
Citations -  10176

Christof M. Kramm is an academic researcher from University of Göttingen. The author has contributed to research in topics: Medicine & Glioma. The author has an hindex of 37, co-authored 142 publications receiving 7513 citations. Previous affiliations of Christof M. Kramm include Harvard University & University of Düsseldorf.

Papers
More filters
Journal ArticleDOI

DNA methylation-based classification of central nervous system tumours

David Capper, +171 more
- 22 Mar 2018 - 
TL;DR: This work presents a comprehensive approach for the DNA methylation-based classification of central nervous system tumours across all entities and age groups, and shows that the availability of this method may have a substantial impact on diagnostic precision compared to standard methods.
Journal ArticleDOI

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

Dominik Sturm, +82 more
- 16 Oct 2012 - 
TL;DR: It is demonstrated that each H3F3A mutation defines an epigenetic subgroup of GBM with a distinct global methylation pattern, and that they are mutually exclusive with IDH1 mutations, which characterize a third mutation-defined subgroup.
Journal ArticleDOI

The landscape of genomic alterations across childhood cancers

Susanne Gröbner, +185 more
- 15 Mar 2018 - 
TL;DR: The data suggest that 7–8% of the children in this cohort carry an unambiguous predisposing germline variant and that nearly 50% of paediatric neoplasms harbour a potentially druggable event, which is highly relevant for the design of future clinical trials.
Journal ArticleDOI

New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs

Dominik Sturm, +122 more
- 25 Feb 2016 - 
TL;DR: It is demonstrated that a significant proportion of institutionally diagnosed CNS-PNETs display molecular profiles indistinguishable from those of various other well-defined CNS tumor entities, facilitating diagnosis and appropriate therapy for patients with these tumors.
Journal ArticleDOI

Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study

TL;DR: This study demonstrates the feasibility of comprehensive, real-time molecular profiling for high-risk paediatric cancer patients and expands upon previous personalised oncology endeavors, and presents a model with considerable interest and practical relevance in the burgeoning era of personalised medicine.